CasePit
AAPLTSLAMSFTNVDAAMZNGOOGLMETAAMDNFLXPLTRCOINJPM
AAPLTSLAMSFTNVDAAMZNGOOGLMETAAMDNFLXPLTRCOINJPM
Post DDLog in
  • Feed
  • Discover
  • Watchlist
  • Messages
  • Profile

Verify your position

Show a βœ“ badge on your posts. Proof beats opinion.

Add a position

Trending now

Promoted

Something missing?

s/wishlist is where features get requested, argued over, and built.

Open s/wishlist β†’

Not financial advice. Prices are delayed. Verified positions reflect a point-in-time check, not current holdings.

CasePit is a community discussion platform. Nothing here is financial advice, an offer, or a recommendation to buy or sell any security. Verified positions show what a member held at the time of verification, not what they hold now. Prices are delayed and provided for information only. Do your own research.

πŸ“± CasePit for iOS is in the works.

  • About
  • Congress
  • Insiders
  • Terms of Service
  • Privacy Policy
  • Risk Notice
  • Imprint
  • Moderation notices
  • Feed
  • Discover
  • +
  • Watchlist
  • Profile

MRVI

Maravai LifeSciences Holdings,

Open
High
Low
Prev close
Volume

About Maravai LifeSciences Holdings,

Maravai LifeSciences Holdings, (MRVI) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $969.4M.

Sector
Healthcare
Industry
Pharmaceutical Preparations
Market cap
$969.4M
EPS (TTM)
$-0.90
Revenue (TTM)
$185.7M
Free cash flow
-$70.7M
Profit margin
-70.4%
Shares outstanding
148M

Financial health: Weak1.7/10

1 strength, 7 concerns. Weakest points: debt to equity, net debt vs cash flow, return on equity and 4 more.

  • Debt to equity: 1.37 (Concern, benchmark < 0.5) β€” Debt of 1.37x equity is high against the 0.5x benchmark. It has deteriorated over the last 4 years.
  • Net debt vs cash flow: β€” (Concern, benchmark < 4 years) β€” Carries $74.9M of net debt while free cash flow is negative, so the debt is not being repaid from the business.
  • Current ratio: 6.60 (Strong, benchmark > 1.5) β€” Short-term assets cover 6.60x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
  • Return on equity: -61.6% (Concern, benchmark > 15%) β€” Earns -61.6% on shareholder equity, well short of the > 15% mark.
  • Gross margin: 18.3% (Concern, benchmark > 40%) β€” Keeps 18.3% of revenue after the direct cost of sales, well short of the > 40% mark.
  • Net margin: -70.4% (Concern, benchmark > 10%) β€” Turns -70.4% of revenue into profit, well short of the > 10% mark.
  • Free cash flow: -$70.7M (Concern, benchmark positive) β€” Burned $70.7M of cash after capital spending, so operations did not fund themselves. It has deteriorated over the last 4 years.
  • Revenue growth: -28.3% (Concern, benchmark > 10%) β€” Revenue changed -28.3% year on year, well short of the > 10% mark.
  • Earnings growth: 9.7% (Watch, benchmark > 10%) β€” Earnings changed 9.7% year on year, short of the > 10% mark.

AI take

AI-generated Β· not financial advice

MRVI news

Promoted

Something missing?

s/wishlist is where features get requested, argued over, and built.

Open s/wishlist β†’

Discussion in s/MRVI